Kiyoi H, Naito K, Ohno R, Saito H, Naoe T
Department of Infectious Diseases, Nagoya University School of Medicine, Japan.
Leukemia. 1998 Apr;12(4):601-9. doi: 10.1038/sj.leu.2400972.
We studied the organization, diversification and clinical significance of the immunoglobulin light chain (IgL) variable region genes expressed in 17 kappa-chain and 16 lambda-chain producing multiple myeloma (MM) samples. The V genes from 31 MM samples had over 84.9% homology to the known germline Vkappa/lambda genes, whereas one Vkappa and one Vlambda gene had only 75.5% and 65.9% homology, respectively. While all five Jkappa segments were equally used, only Jlambda-1 or Jlambda-2/3 was used among seven Jlambda segments. N nucleotide addition was found at two Vkappa-Jkappa and five Vlambda-Jlambda junctions. The lambda-chain complementarity determining region (CDR)-3 was longer and more variable than the kappa-chain CDR-3 mainly due to junctional flexibility of Vlambda and Jlambda segments. Somatic mutations were more frequent in the Jlambda than the Jkappa segments, and were distributed in the CDR-3 as well as the frame work region (FWR)-4. Those of the Jkappa segments, however, were limited to FWR-4. In FWR-4, replacement mutations were clustered at codon 106 of kappa-chain and 103 of lambda-chain. Thus nucleotide mutation or conservation was dependent on position, indicating a structural necessity of IgL for the development of myeloma cells in addition to a non-random distribution of mutations. There was no characteristic IgL sequence according to the isotype of M-protein, clinical stage or renal complication.
我们研究了在17个产生κ链和16个产生λ链的多发性骨髓瘤(MM)样本中表达的免疫球蛋白轻链(IgL)可变区基因的组织、多样性及临床意义。31个MM样本中的V基因与已知种系Vκ/λ基因具有超过84.9%的同源性,而一个Vκ基因和一个Vλ基因的同源性分别仅为75.5%和65.9%。虽然所有五个Jκ片段被同等利用,但在七个Jλ片段中仅使用Jλ-1或Jλ-2/3。在两个Vκ-Jκ和五个Vλ-Jλ连接点发现了N核苷酸添加。λ链互补决定区(CDR)-3比κ链CDR-3更长且更具变异性,这主要归因于Vλ和Jλ片段的连接灵活性。体细胞突变在Jλ片段中比在Jκ片段中更频繁,并且分布在CDR-3以及框架区(FWR)-4中。然而,Jκ片段的体细胞突变仅限于FWR-4。在FWR-4中,置换突变聚集在κ链的第106密码子和λ链的第103密码子处。因此,核苷酸突变或保守性取决于位置,这表明IgL除了突变的非随机分布外,对骨髓瘤细胞的发育具有结构必要性。根据M蛋白的同种型、临床分期或肾脏并发症,没有特征性的IgL序列。